TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed...
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung,...
PRESS RELEASE: 28 August 2023, 7:00 AM CEST Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders Mechelen, Belgium, 28...
HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to...
PRESS RELEASE: 24 August 2023, 07:00 CEST BIOCARTIS ANNOUNCES 2023 HALF-YEAR RESULTS ON 26 SEPTEMBER 2023 Mechelen, Belgium, 24 August 2023 –...
Oslo, 22 August 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its...
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T...
South Perth, Australia--(Newsfile Corp. - August 17, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("AHI" or the...
NCI award (non-dilutive grant) further validates novel personalized off-the-shelf immunotherapy approach; and may facilitate future non-dilutive funding opportunitiesPHILADELPHIA and VANCOUVER,...
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023...
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024...
Highlights AHI enters a second commercial agreement in the UAE.IntelliGen Founders have worked with, and within the Government, Healthcare needs...
Presented at the 2023 American Academy of Dermatology Innovation Academy, the findings demonstrate the potential for DermaSensor’s device to help...
Advances TriSalus’ Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and...
Trial Results Expected in Mid-2024WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical...
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr....
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call...
BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6...